Sign in
Taking people in FrancePhase 2

Testing probenecid for repeated seizures during epilepsy hospital monitoring

Tests probenecid to stop repeated seizures in adults with focal epilepsy during hospital monitoring.

Key facts

Who runs it
Fondation A De Rothschild
Where
Bron, Grenoble Cedex 9, Lille Cedex, Marseille, Paris, Rennes, Rouen Cedex, and Toulouse, FranceSee the 10 sites
Registry title
Efficacy of probenecid on cluster seizures during dosage reduction of Anti Seizure Medication (ASM) in presurgical focal epilepsy video-EEG monitoring
Status
Recruiting
Phase
Phase 2
People taking part
192 people, planned
Started
28 Jul 2026
Expected to end
1 Nov 2028
Type of study
Interventional
Record updated
1 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 6 to 50 with focal epilepsy who are having video-EEG monitoring before surgery and who have a cluster of seizures when their seizure medicine is reduced.

Age
6 to 50 years old. Children and teenagers must weigh more than 20 kg (44 lb).
Sex
Men and women can join.
Disease stage
Focal epilepsy that needs video-EEG recording in a hospital epilepsy unit before surgery, with planned stopping of seizure medicine to bring on seizures, or without lowering the dose if seizures usually come anyway.
Earlier treatment
Planned reduction or withdrawal of anti-seizure medicine is part of the monitoring. Taking acetylsalicylic acid or methotrexate is not allowed.

Main reasons for not taking part

  • Allergy to probenecid or to any of its other ingredients
  • Pregnant or breast-feeding women
  • Known kidney problems (creatinine clearance below 50 ml/min)
  • Kidney stone tendency, acute gout attack, or high uric acid caused by cancer treatment, a bone marrow disease, or too much uric acid production
  • Taking acetylsalicylic acid or methotrexate, or taking part in another drug trial

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Patients between 6 and 50 years old
  • Adults, of any weight, who are free from malnutrition or any condition affecting their physiology to any significant degree; or children and adolescents weighing more than 20 kg
  • With focal seizures epilepsy
  • Requiring video-EEG recording in Epilepsy Monitoring Units (EMU) for the presurgical evaluation of a focal epilepsy, with planned Anti-Seizure Medication (ASM) withdrawal in order to precipitate seizure occurrence, or without dose reduction in the case of epilepsy whose natural history suggests the appearance of seizures without withdrawal
  • Able to take an oral therapy
  • Ability to record the patient > 12 hours after the second seizure of the cluster
  • Having received informed information about the study and having signed a consent form to participate in the study. Written consent of both holders of parental authority for minor patients
  • Affiliated or beneficiary to a social security scheme

Who cannot take part

  • Treatment with the following drugs: acetylsalicylic acid and/or methotrexate (Note: the following medications require caution when co-administered: penicillins, quinolones, cephalosporins including cefadroxil, paracetamol, naproxen, indomethacin, ketoprofen, lorazepam, thiopental, olanzapine, famotidine, clofibrate, valaciclovir, aciclovir, ganciclovir, cidofovir, zidovudine, angiotensin-converting enzyme inhibitors and dyprophylline)
  • Participation in an interventional clinical study (drug)
  • Hyperuricemia secondary to cancer chemotherapy, radiotherapy or myeloproliferative neoplasia
  • Hypersensitivity to PBN or to any of the excipients (Microcrystalline cellulose, Hypromellose, Sodium carboxymethylamidon, Colloidal anhydrous silica, Magnesium stearate)
  • Known or identified impaired renal function (creatinine clearance < 50 ml/min) in children and adults
  • Pregnant or breast-feeding woman
  • Lithiasis diathesis
  • Acute gout attack
  • Primary hyperuricemia due to overproduction of uric acid
  • Patient benefiting from legal protection

Where in France

  • Hospices Civils de LyonBron, FranceTaking people
  • Centre Hospitalier Universitaire Grenoble AlpesGrenoble Cedex 9, FranceTaking people
  • Centre Hospitalier Universitaire De LilleLille Cedex, FranceTaking people
  • Centre Hospitalier Regional De MarseilleMarseille, FranceTaking people
  • Assistance Publique Hopitaux de ParisParis, FranceTaking people
  • Fondation A. de RothschildParis, FranceTaking people
  • Groupe Hospitalier Universitaire Paris Psychiatrie Et NeuroscienceParis, FranceTaking people
  • Centre Hospitalier Universitaire de RennesRennes, FranceTaking people
  • Centre Hospitalier Universitaire RouenRouen Cedex, FranceTaking people
  • Centre Hospitalier Universitaire de ToulouseToulouse, FranceTaking people

About the trial

What the trial wants to find out

To assess the efficacy of PBN administration on the cessation of seizure recurrence in patients experiencing a cluster seizure upon discontinuation of ASM for pre-surgical hospital video EEG monitoring.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Efficacy of probenecid on cluster seizures during dosage reduction of Anti Seizure Medication (ASM) in presurgical focal epilepsy video-EEG monitoring
Plain-language title
Testing probenecid for repeated seizures during epilepsy hospital monitoringGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
1 October 2026